secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2026-09-14T10:20:15+00:00
Accession:  0001193125-26-389785
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics and Merck collaborate on PSV359 + Keytruda for FAP-α solid tumors
--------------------------------------------------------------------------------

- Clinical collaboration with Merck (NYSE: MRK) to evaluate [212Pb]PSV359 plus Keytruda in FAP-α positive solid tumors.
- Amendment to ongoing Phase 1/2a study (NCT06710756) in NSCLC and colorectal cancer; first three monotherapy dose cohorts completed enrollment.
- Merck supplies pembrolizumab at no cost; Perspective sponsors the study.
- FAP-α expressed in majority of solid tumors; combination aims to reshape tumor microenvironment and improve outcomes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000119312526389785/0001193125-26-389785-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000119312526389785/catx-20260914.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-389785

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer